




# PHARMACEUTICAL 2023

Corvus Pharmaceuticals Inc.  
Rank 171 of 446





# PHARMACEUTICAL 2023

Corvus Pharmaceuticals Inc.  
Rank 171 of 446

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 91% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	43,664
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,752
Liabilities, Non-Current	1,373
Other Assets	24,223
Other Compr. Net Income	-2,432
Other Expenses	0
Other Liabilities	0
Other Net Income	-8,742
Other Revenues	0
Property and Equipment	353
Research and Development	24,468
Selling, General and Administrative Expense	8,097

Output Variable	Value in 1000 USD
Assets	68,240
Liabilities	12,125
Expenses	32,565
Revenues	0
Stockholders Equity	56,115
Net Income	-41,307
Comprehensive Net Income	-42,523
Economic Capital Ratio	134%